Inicia sesión Registrate Mi Biblioteca idioma

Idioma

biblioteca idioma abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará la selección de artículos sobre Trastornos del Movimiento clasificados según los 11 tipos establecidos por International Parkinson & Movement Disorder Society.

Corea y enfermedad de Huntington

450 ARTíCULOS , VIENDO DEL 91 AL 105

PUBMED

Theory of mind and empathy in preclinical and clinical Huntington's disease.

Adjeroud N, Besnard J, El Massioui N, Verny C, Prudean A, Scherer C, Gohier B, Bonneau D, Allain P.

Soc Cogn Affect Neurosci. 2016 Jan;11(1):89-99. doi: 10.1093/scan/nsv093.

0

0

0

PUBMED

Exploring the Structural Relationship Between Interviewer and Self-Rated Affective Symptoms in Huntington's Disease.

Maltby J, Dale M, Underwood M, Rickards H, Callaghan J; REGISTRY Investigators of the European Huntington’s Disease Network..

J Neuropsychiatry Clin Neurosci. 2016 Summer;28(3):236-8. doi: 10.1176/appi.neuropsych.15090237.

0

0

0

PUBMED

PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically.

Dickey AS, Pineda VV, Tsunemi T, Liu PP, Miranda HC, Gilmore-Hall SK, Lomas N, Sampat KR, Buttgereit A, Torres MJ, Flores AL, Arreola M, Arbez N, Akimov SS, Gaasterland T, Lazarowski ER, Ross CA, Yeo

Nat Med. 2016 Jan;22(1):37-45. doi: 10.1038/nm.4003.

0

0

0

PUBMED

Clinics in diagnostic imaging (166). Nonketotic hyperglycaemic chorea-hemiballismus.

Goh LW, Chinchure D, Lim TC.

Singapore Med J. 2016 Mar;57(3):161-4; quiz 165. doi: 10.11622/smedj.2016052.

0

0

0

PUBMED

Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.

Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM.

Mol Pharmacol. 2016 Mar;89(3):364-75. doi: 10.1124/mol.115.101980.

0

0

0

PUBMED

Metabolite mapping reveals severe widespread perturbation of multiple metabolic processes in Huntington's disease human brain.

Patassini S, Begley P, Xu J, Church SJ, Reid SJ, Kim EH, Curtis MA, Dragunow M, Waldvogel HJ, Snell RG, Unwin RD, Faull RL, Cooper GJ.

Biochim Biophys Acta. 2016 Sep;1862(9):1650-62. doi: 10.1016/j.bbadis.2016.06.002.

0

0

0

PUBMED

Mitochondria-targeted molecules MitoQ and SS31 reduce mutant huntingtin-induced mitochondrial toxicity and synaptic damage in Huntington's disease.

Yin X, Manczak M, Reddy PH.

Hum Mol Genet. 2016 May 1;25(9):1739-53. doi: 10.1093/hmg/ddw045.

0

0

0

PUBMED

Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease.

Miniarikova J, Zanella I, Huseinovic A, van der Zon T, Hanemaaijer E, Martier R, Koornneef A, Southwell AL, Hayden MR, van Deventer SJ, Petry H, Konstantinova P.

Mol Ther Nucleic Acids. 2016 Mar 22;5:e297. doi: 10.1038/mtna.2016.7.

0

0

0

PUBMED

Chorea as the Neurological Symptom of Delayed Encephalopathy After Carbon Monoxide Intoxication in a Child.

Ubaidulhaq M, Lee YA, Jiang H.

Neurohospitalist. 2016 Jul;6(3):130-1. doi: 10.1177/1941874416628606. No abstract available.

0

0

0

PUBMED

Enhanced Store-Operated Calcium Entry Leads to Striatal Synaptic Loss in a Huntington's Disease Mouse Model.

Wu J, Ryskamp DA, Liang X, Egorova P, Zakharova O, Hung G, Bezprozvanny I.

J Neurosci. 2016 Jan 6;36(1):125-41. doi: 10.1523/JNEUROSCI.1038-15.2016.

0

0

0

PUBMED

GluN3A promotes NMDA spiking by enhancing synaptic transmission in Huntington's disease models.

Mahfooz K, Marco S, Martínez-Turrillas R, Raja MK, Pérez-Otaño I, Wesseling JF.

Neurobiol Dis. 2016 Sep;93:47-56. doi: 10.1016/j.nbd.2016.04.001.

0

0

0

PUBMED

Adult-onset Sydenham's chorea or drug-induced movement disorder? A case report.

Delaruelle Z, Honoré PJ, Santens P.

Acta Neurol Belg. 2016 Sep;116(3):399-400. doi: 10.1007/s13760-015-0537-6. No abstract available.

0

0

0

PUBMED

Problem solving, impulse control and planning in patients with early- and late-stage Huntington's disease.

Mörkl S, Müller NJ, Blesl C, Wilkinson L, Tmava A, Wurm W, Holl AK, Painold A.

Eur Arch Psychiatry Clin Neurosci. 2016 Oct;266(7):663-71. doi: 10.1007/s00406-016-0707-4.

0

0

0

PUBMED

Activating transcription factor 6 derepression mediates neuroprotection in Huntington disease.

Naranjo JR, Zhang H, Villar D, González P, Dopazo XM, Morón-Oset J, Higueras E, Oliveros JC, Arrabal MD, Prieto A, Cercós P, González T, De la Cruz A, Casado-Vela J, Rábano A, Valenzuela C, Gutierrez-

J Clin Invest. 2016 Feb;126(2):627-38. doi: 10.1172/JCI82670.

0

0

0

Comentarios

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo HONcode Logo WIS

En colaboración con:

Zambon Neuroacademy